Introduction {#s0001}
============

Rotavirus (RV) is an important cause of severe gastroenteritis (GE) in children younger than 5 years of age throughout the world.[@cit0001] Estimates in 2008 from the World Health Organization (WHO) indicated that each year approximately 453,000 child deaths worldwide could be associated with RVGE.[@cit0003] In China, approximately 13,400 children less than 5 years of age died from RV in 2002, of which 70% of cases occurred in rural areas.[@cit0004] Between 2003 and 2007, 48% of children hospitalized in China with diarrhea had RV. The highest burden of disease was observed in children younger than 2 years of age.[@cit0005]

Vaccination as a primary prophylactic measure, may substantially reduce the disease burden associated with RVGE.[@cit0003] Two, live-attenuated, oral RV vaccines are currently available in many countries: a monovalent human RV vaccine (RIX4414; *Rotarix*™, GSK, Belgium) and a pentavalent human-bovine RV vaccine (*Rotateq*→, Merck & Co., USA).[@cit0006] In China, the Lanzhou lamb RV vaccine (LLR; Lanzhou Institute of Biomedical Products, China) is the only currently approved RV vaccine; it has an immunization coverage of 25%.[@cit0009]

RIX4414 is recommended as a 2-dose schedule in infants, which are often co-administered with other routine childhood vaccines. Although data are available on the immunogenicity of RIX4414 when co-administered with recommended routine childhood vaccines in other countries,[@cit0010] this study was undertaken to obtain additional data in Chinese infants. The primary results of the trial that evaluated the efficacy and safety of RIX4414 against severe RVGE in Chinese infants during the first 2 years of life have been published elsewhere.[@cit0013] In this paper, we present the immunogenicity and reactogenicity of RIX4414 with co-administered childhood vaccines.

Results {#s0002}
=======

Study participants and demographics {#s0002-0001}
-----------------------------------

A total of 918 infants were included in the Total Vaccinated Cohort (TVC) for immunogenicity, of whom 612 and 306 were included in the separate administration and co-administration cohorts, respectively ([Fig. 1](#f0001){ref-type="fig"}). The According-to-Protocol (ATP) immunogenicity analysis included 511 subjects in the separate administration cohort (RIX4414 = 257; placebo = 254) and 275 in the co-administration cohort (RIX4414 = 136; placebo = 139). The demographic characteristics of the RIX4414 (N=391) or placebo (N=393) groups and both sub-cohorts are presented in [Table 1](#t0001){ref-type="table"}. All infants in this study were Chinese. Figure 1.Study profile for immunogenicity cohorts. Table 1.Demographic characteristics (ATP immunogenicity cohort). RIX4414 group (N = 391)Placebo group (N = 393)Seperate cohort (N = 511)Co-administration cohort (N = 275)Mean age (in weeks) ± SDRIX4414/placebo dose 110.0 (2.5)10.1 (2.4)10.1 (2.9)10.0 (1.3) RIX4414/placebo dose 214.5 (2.6)14.5 (2.5)14.6 (3.0)14.5 (1.3) OPV dose 1---------10.0 (1.3) OPV dose 2/ DTPa dose 1---------14.5 (1.3) OPV dose 3/ DTPa dose 2---------19.0 (1.4) DTPa dose 3---------23.5 (1.6)Gender (n \[%\])Female196 (50.1)198 (50.4)253 (49.5)138 (50.2) Male195 (49.9)195 (49.6)258 (50.5)137 (49.8)[^3][^4][^5][^6][^7][^8]

Immunogenicity {#s0002-0002}
--------------

One month after the second RIX4414 dose, 71.1% (95% confidence interval \[CI\]: 66.3--75.5) of all RIX4414 recipients seroconverted for anti-RV Immunoglobulin A (IgA) compared with 5.6% (95% CI: 3.5--8.4) of placebo recipients. At one year of age, 64.3% (95% CI: 59.2--69.2) and 38.2% (95% CI: 33.3--43.2) of RIX4414 and placebo recipients, respectively, were seropositive for anti-RV IgA antibodies. One month after the second RIX4414 dose, the anti-RV IgA antibody geometric mean concentration (GMC) in seropositive subjects was 213.2 (95% CI: 180.3--252.0) in all RIX4414 recipients and 196.4 (95% CI: 108.9--354.3) in placebo recipients. At one year of age, the anti-RV IgA antibody GMCs in seropositive subjects were 128.4 (95% CI: 110.5--149.2) and 140.3 (95% CI: 118.4--166.4) in all RIX4414 and placebo recipients, respectively.

One month after the second RIX4414 dose, anti-RV IgA seroconversion rates were 74.7% (95% CI: 68.9--79.9) and 64.2% (95% CI: 55.4--72.3) in the separate and co-administration cohorts, respectively, ([Fig. 2a](#f0002){ref-type="fig"}). At one year of age, 71.5% (95% CI: 65.5--77.1) of RIX4414 recipients in the separate cohort and 50.0% (95% CI: 40.9--59.1) in the co-administration cohort remained seropositive for anti-RV IgA antibodies ([Fig. 2a](#f0002){ref-type="fig"}). Figure 2.Anti-RV IgA seroconversion (one month post-dose-2)/seropositivity rates (at one year of age) and GMCs in seropositive subjects (separate and co-administration cohort \[vaccine group\]) (ATP- cohort): (**a**) Seroconversion / Seropositivity rates; (**b**) GMCs.

One month after the second dose of RIX4414, 3.5% and 9.4% of placebo recipients in the separate and co-administration cohorts respectively, were seropositive for anti-RV IgA due to natural infection. At one year of age, the anti-RV IgA seropositivity rates had also increased in the placebo recipients (separate cohort = 46.8%; co-administration cohort = 21.8%).

Anti-RV IgA antibody GMCs rose sharply from pre-vaccination until one month post-dose 2 and decreased at one year of age in subjects who received RIX4414 in both the separate and co-administration cohorts ([Fig. 2b](#f0002){ref-type="fig"}).

One month after the third dose of combined diphtheria-tetanus-acellular pertussis (DTPa, *Infanrix*™, GSK, Belgium), infants who received RIX4414/placebo concomitantly with DTPa and the oral poliovirus vaccine (OPV, Institute of Medical Biology, Chinese Academy of Medical Sciences, China), had 100% seroprotection rates against diphtheria and tetanus. Seropositivity rates against pertussis toxoid (PT), filamentous haemagglutinin (FHA) and pertactin (PRN) were 100% in both the RIX4414 and placebo groups. The overall vaccine response rates for anti-PT and anti-FHA were 100% in both the RIX4414 and placebo groups, and were 98.4% (95% CI: 94.5--99.8) and 99.3% (95% CI: 96.1--100), respectively against PRN. Two months after the third dose of OPV, seroprotection rates for anti-poliovirus types 1, 2 and 3 were over 99% in both the RIX4414 and placebo groups. The corresponding antibody GMCs against the co-administered vaccine antigens are presented in [Table 2](#t0002){ref-type="table"}. Table 2.Immune responses toward co-administered vaccines one month after the third vaccine dose (co-administration cohort). Seroprotection/ SeropositivityGeometric mean concentrationAntibodyGroupNn% (95% CI)value (95% CI)Anti-Diphtheria ≥ 0.1 IU/mlRIX4414133133100 (97.3; 100)0.4 (0.3; 0.4) Placebo139139100 (97.4; 100)0.3 (0.3; 0.4)Anti-Tetanus ≥ 0.1 IU/mlRIX4414133133100 (97.3; 100)1.3 (1.3; 1.3) Placebo139139100 (97.4; 100)1.3 (1.2; 1.5)Anti-PT ≥ 5 EU/mlRIX4414133133100 (97.3; 100)88.9 (84.9; 93.2) Placebo139139100 (97.4; 100)90.5 (86.4; 94.8)Anti-FHA ≥ 5 EU/mlRIX4414133133100 (97.3; 100)59.5 (55.8; 63.5) Placebo139139100 (97.4; 100)65.8 (61.3; 70.5)Anti-PRN ≥ 5 EU/mlRIX4414133133100 (97.3; 100)41.9 (37.6; 46.5) Placebo139139100 (97.4; 100)50.8 (44.3; 58.1)Anti-Polio 1 ≥ 8 ED50RIX4414136136100 (97.3; 100)2101.1 (1734.8; 2544.8) Placebo139139100 (97.4; 100)2259.4 (1844.4; 2767.9)Anti-Polio 2 ≥ 8 ED50RIX4414136136100 (97.3; 100)402.5 (334.8; 483.9) Placebo139139100 (97.4; 100)425.1 (371.0; 487.1)Anti-Polio 3 ≥ 8 ED50RIX441413613599.3 (96.0; 100)426.6 (342.7; 531.0) Placebo13913899.3 (96.1; 100)360.3 (303.0; 428.3)[^9][^10][^11][^12]

Reactogenicity {#s0002-0003}
--------------

### All symptoms during the 8-day post-vaccination follow-up period {#s0002-0003-0001}

In the TVC excluding subjects in the co-administration cohort, the incidence of all symptoms (solicited \[general only\] and unsolicited) was 44.2% (95% CI: 41.7--46.8) and 47.3% (95% CI: 44.8--49.8) in the RIX4414 and placebo groups, respectively. Grade 3 symptoms were similar in the RIX4414 (11.2% \[95% CI: 9.7--12.9\]) and placebo groups (10.1% \[95% CI: 8.6--11.7\]) ([Table 3](#t0003){ref-type="table"}). Table 3.Solicited symptoms (any symptom and general symptoms). Total vaccinated cohort Excluding co-administration cohortCo-administration cohort RIX4414 (N=1513)Placebo (N=1514)RIX4414 (N=153)Placebo (N=153)  % (95% CI)% (95% CI)% (95% CI)% (95% CI)Any symptom44.2 (41.7; 46.8)47.3 (44.8; 49.8)57.5 (49.3; 65.5)52.9 (44.7; 61.1)Grade 311.2 (9.7; 12.9)10.1 (8.6; 11.7)5.2 (2.3; 10.0)4.6 (1.9; 9.2)Causally related to vaccination15.8 (14.0; 17.7)14.7 (12.9; 16.5)3.9 (1.5; 8.3)2.6 (0.7; 6.6)General symptomsCough/runny noseAll20.7 (18.7; 22.8)24.2 (22.0; 26.4)------ Grade 31.3 (0.8; 2.0)0.5 (0.2; 1.0)------DiarrheaAll8.4 (7.0; 9.9)8.1 (6.8; 9.6)------ Grade 33.6 (2.8; 4.7)4.0 (3.0; 5.1)------Irritability/FussinessAll27.4 (25.2; 29.8)29.6 (27.3; 32.0)36.6 (29.0; 44.8)34.0 (26.5; 42.1) Grade 32.8 (2.1; 3.8)2.6 (1.8; 3.5)3.3 (1.1; 7.5)2.6 (0.7; 6.6)Loss of appetiteAll16.7 (14.9; 18.7)16.5 (14.7; 18.5)28.1 (21.1; 35.9)20.9 (14.8; 28.2) Grade 30.2 (0.0; 0.6)0.5 (0.2; 1.0)0.7 (0.0; 3.6)1.3 (0.2; 4.6)FeverAll5.5 (4.4; 6.8)6.9 (5.6; 8.3)3.9 (1.5; 8.3)4.6 (1.9; 9.2) Grade 30.1 (0.0; 0.4)0.1 (0.0; 0.5)0.0 (0.0; 2.4)0.7 (0.0; 3.6)VomitingAll14.1 (12.4; 15.9)15.3 (13.5; 17.2)------ Grade 35.3 (4.2; 6.5)5.0 (3.9; 6.2)------DrowsinessAll------28.8 (21.7; 36.6)24.8 (18.2; 32.5) Grade 3------2.0 (0.4; 5.6)0.7 (0.0; 3.6)Gastrointestinal (nausea, vomiting, diarrhea and/or abdominal pain)All------28.1 (21.1; 35.9)24.8 (18.2; 32.5) Grade 3------1.3 (0.2; 4.6)1.3 (0.2; 4.6)[^13][^14]

In the co-administration cohort, all symptoms (solicited \[local and general\] and unsolicited) were reported for 57.5% (95% CI: 49.3--65.5) of RIX4414 and 52.9% (95% CI: 44.7--61.1) of placebo recipients. Grade 3 symptoms were reported for fewer than 6.0% of infants in both the RIX4414 and placebo groups ([Table 3](#t0003){ref-type="table"}).

### Solicited general AEs (8-day post-vaccination follow-up period) {#s0002-0003-0002}

Of RIX4414 recipients, 44.2% (95% CI: 41.7--46.8) in the TVC excluding subjects in the co-administration cohort and 57.5% (95% CI: 44.7--61.1) belonging to the co-administration cohort recorded any symptoms.

In the TVC excluding subjects in the co-administration cohort, irritability/fussiness was the most common solicited general symptom in both the RIX4414 and placebo groups, followed by cough/runny nose. Diarrhea was the most common grade 3 solicited general symptom observed in both the RIX4414 and placebo groups ([Table 3](#t0003){ref-type="table"}). In the co-administration cohort, irritability/fussiness (all and grade 3) was the most commonly reported solicited general symptom in both the RIX4414 and placebo groups, followed by drowsiness and gastrointestinal symptoms ([Table 3](#t0003){ref-type="table"}).

### Solicited local AEs (8-day post-vaccination follow-up period) {#s0002-0003-0003}

In infants who received concomitant DTPa, redness was the most common solicited local symptom, which occurred in 13.3% (95% CI: 8.3--19.8) and 8.6% (95% CI: 4.7--14.3) of RIX4414 and placebo recipients, respectively. Injection site pain (RIX4414 = 9.3% \[95% CI: 5.2--15.2\]; placebo = 6.0% \[95% CI: 2.8--11.0\]) and swelling (RIX4414 = 8.7% \[95% CI: 4.7--14.4\]; placebo = 4.0% \[95% CI: 1.5--8.4\]) were reported at similar frequencies in both the RIX4414 and placebo groups. Grade 3 pain was reported in 2 RIX4414 recipients and grade 3 redness in one placebo recipient.

Discussion {#s0003}
==========

This study evaluated the efficacy, immunogenicity and safety of RIX4414 in Chinese infants.

Primary efficacy, and safety results from the trial have been previously published,[@cit0013] and this paper presents the results for the secondary objective, the immune response of routine childhood vaccines (DTPa and OPV) when administered either separately from or concomitantly with RIX4414/placebo.

In our study, one month after the second dose of RIX4414, the anti-RV IgA seroconversion rate was 64.2% (95% CI: 55.4--72.3) in the co-administration cohort and 74.7% (95% CI: 68.9--79.9) in the separate cohort; the corresponding anti-RV IgA antibody GMCs in seropositive subjects was 275.8 (95% CI: 193.1--393.8) and 189.9 (95% CI: 158.3--227.9), respectively. The anti-RV IgA seroconversion rate in the co-administration cohort are consistent with studies conducted in Bangladesh (56.5% \[95% CI: 44.0--68.4\]) and South Africa (57.1% \[95% CI: 44.7--68.9\]) in which RIX4414 was co-administered with OPV.[@cit0014] Although the anti-RV IgA seroconversion rate in the co-administration cohort seems to be lower than that in the separate cohort, the 95% CIs overlapped. Interestingly, in the study from Bangladesh, a similar trend was observed, where the anti-RV IgA seroconversion rate was 66.7% (95% CI: 54.0--77.8) when RIX4414 and OPV were administered separately.[@cit0014] This difference in anti-RV IgA seroconversion rates between the groups receiving RIX4414 concomitantly or separately with routine OPV could be attributed to interference between RIX4414 and OPV when the 2 vaccines are co-administered. Research has shown that since OPV and RV vaccines contain live, attenuated vaccine virus strains which replicate in the gut, the potential for mutual interference exists following the first dose of RV vaccine.[@cit0016] A previous study in South Africa showed that OPV co-administration interfered with the immune response observed after the first dose of RIX4414, but was overcome after the second dose of RIX4414; there was no interference with the immune response to OPV.[@cit0016] In 2 studies from Latin America, one with and the other without co-administered OPV, similar efficacy results against severe RVGE were observed \[without OPV: 84.8% (95% CI: 71.1--92.7); with OPV: 84.3% (95% CI: 59.0--94.9)\].[@cit0006]

Anti-RV IgA seroconversion rates are also affected by the socio-economic status of a country. The anti-RV IgA seroconversion rate in all RIX4414 recipients one month after the second dose (71.1% \[95% CI: 66.3--75.5\]) was lower than that which has been observed in Europe (86.5% \[95% CI: 83.9--88.8\]), Japan (85.3% \[95% CI: 68.9--95.0\]), Korea (88.1% \[95% CI: 84.0--91.4\]), Singapore (91.0% \[95% CI: 85.2--95.1\]) and Hong Kong (97.5% \[95% CI: 86.8--99.9\]); all countries whose populations belong to a higher socio-economic status compared our study population.[@cit0011] However, in South Africa and India, which have comparable socio-economic conditions to China, anti-RV IgA seroconversion rates comparable with the current study have been reported.[@cit0023]

At one year of age, anti-RV seropositivity rates in RIX4414 recipients were higher in the separate cohort (71.5% \[95% CI: 65.5--77.1\]) as compared with the co-administration cohort (50.0% \[95% CI: 40.9--59.1\]). This difference could be due to OPV co-administration, but the GMC values calculated on seropositive subjects in the 2 sub-cohorts were in the same range (separate cohort=141.3 \[95% CI: 118.0--169.1\]; co-administration cohort=97.8 \[95% CI: 75.0--127.6\]). Furthermore, studies conducted in Latin America showed similar efficacy results against severe RVGE when RIX4414 was administered with and without OPV.[@cit0006]

The seroconversion rate one month after the second dose of RIX4414 (71.1% \[95% CI: 66.3--75.5\]) and the seropositivity rate at one year of age (64.3% \[95% CI: 59.2--69.2\]) in the pooled RIX4414 group are comparable with the observed estimate of vaccine efficacy against severe RVGE at one year of age (75%),[@cit0013] implying that the anti-RV IgA seroconversion and seropositivity rates could be reasonable estimates for vaccine efficacy. A recent paper has also suggested that anti-RV IgA seropositivity may serve as a useful correlate of RIX4414 efficacy against RVGE.[@cit0025] Further studies to support this may be needed. On the other hand, the observed seropositivity rate at one year of age in placebo recipients in the separate cohort (46.8% \[95% CI: 40.5--53.2\]) indicates a high rate of natural RV infection in this population during the first year of life, and supports the need for the early RV prevention.

As observed in studies conducted in the United States, Europe, Singapore and Latin America, we demonstrated no interference between RIX4414 and DTPa when routinely administered, with respect to the seropositivity/seroprotection rates and GMCs against the DTPa antigens.[@cit0010] The OPV seroprotection rates (\>99%) observed in this study were higher than those seen in Bangladesh (69.6%--98.5%),[@cit0014] but similar to those recorded in South Africa (\>98%) and Latin America (\>98%).[@cit0017] Despite suggested OPV interference, RIX4414 was immunogenic when co-administered with OPV and did not interfere with the OPV seroprotection rates, demonstrating that the RIX4414 vaccine had no impact on the immune response of the routinely co-administered vaccines.

Overall, the reactogenicity profiles were similar in the RIX4414 and placebo groups in both sub-cohorts. In addition, co-administration with routine childhood vaccines was not associated with an increase in solicited general symptoms. As has been previously observed, irritability was the most common solicited general symptom reported in both sub-cohorts.[@cit0014]

The results of this study should be interpreted bearing in mind that immunogenicity and reactogenicity were secondary objectives and the study was not powered to draw definitive conclusions. It is also important to consider that infants were mostly enrolled from rural areas in the Guangxi Province, the southern part of China, and that this study population may not be fully representative of the infant population in China as a whole.

In conclusion, our study shows that 2 oral doses of the liquid formulation of RIX4414 are immunogenic and well-tolerated in Chinese infants and do not interfere with the immunogenicity and reactogenicity of co-administered DTPa and OPV vaccines. These data support the concomitant administration of RIX4414 with routine childhood vaccines in China.

Materials and methods {#s0004}
=====================

Study design and participants {#s0004-0001}
-----------------------------

This phase III, double-blind, randomized, placebo-controlled study (NCT01171963) was conducted at 4 centers in China between August 2010 and May 2012. Healthy infants aged 6--16 weeks were randomized (1:1) to receive 2 doses of either RIX4414 or placebo according to a 0, 1 month schedule. A subset of infants from the primary efficacy cohort[@cit0013] was grouped into 2 immunogenicity sub-cohorts. Infants in the separate cohort received the recommended childhood vaccines (DTPa and OPV) separately from RIX4414/placebo while those in the co-administration cohort received DTPa and OPV concomitantly with RIX4414/placebo ([Fig. 3](#f0003){ref-type="fig"}). The pooled cohort for immunogenicity comprised the 2 combined sub-cohorts. Exclusion criteria were described in the primary report.[@cit0013] Figure 3.Time points of vaccine administration and blood sampling.

The study was carried out in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The Institutional Ethics Committee of each participating center reviewed and approved all study-related documents. Parents/guardians provided written informed consent before any study procedures were performed.

Vaccines {#s0004-0002}
--------

A single dose of liquid RIX4414 vaccine (*Rotarix*™, GSK, Belgium) contained at least 10^6.0^ median cell culture infectious doses (CCID~50~) of live, attenuated human RV strain. The placebo (GSK, Belgium) contained the same constituents as RIX4414 vaccine without any viral content. The DTPa vaccine (*Infanrix*™, GSK, Belgium) contained diphtheria toxoid (≥30 IU), tetanus toxoid (≥40 IU), PT (25 µg), FHA (25 µg) and PRN (8 µg); OPV vaccine (Institute of Medical Biology, Chinese Academy of Medical Sciences) contained total polio-virus not less than 6.15 lg CCID~50~, ≥6.0 Ig CCID~50~ of poliovirus type 1, ≥5.0 Ig CCID~50~ of poliovirus type 2, and ≥5.5 Ig CCID~50~ of poliovirus type 3 per dose.

RIX4414, OPV and placebo were all administered orally, while the DTPa vaccine was administered intramuscularly into the left anterolateral thigh.

Immunogenicity {#s0004-0003}
--------------

The blood sampling schedule is shown in [Fig. 3](#f0003){ref-type="fig"}. Anti-RV IgA antibody concentrations were measured using an in-house enzyme-linked immunosorbent assay (ELISA; assay cut-off = 20 U/ml). Seroconversion was defined as the appearance of anti-RV IgA antibodies (≥20 U/ml) in the sera of infants who were seronegative before vaccination.

An ELISA technique developed by The National Institutes for Food and Drug Control, China was used to antibodies against diphtheria, tetanus, PT, FHA and PRN.[@cit0029] Anti-polio antibodies were assessed using a microneutralization test adapted from the WHO guidelines (assay cut-off = 8 ED~50~).[@cit0032] Seroprotection was defined as an antibody concentration of ≥0.1 IU/ml for diphtheria and tetanus and 1:8 dilution for poliovirus types 1, 2, and 3. Seropositivity was defined as ≥5 EL.U/ml for each of the pertussis antigens. Vaccine response was evaluated for anti-PT and anti-FHA (defined as ≥20 EL.U/ml), and anti-PRN (calculated as ≥4-fold increase in antibody concentration from pre- to post-vaccination) during the efficacy follow-up period (2 weeks post-dose 2 of RIX4414 up to study end).

Reactogenicity {#s0004-0004}
--------------

Solicited general symptoms (fever, fussiness/irritability, loss of appetite, cough/runny nose, diarrhea and vomiting) were recorded in diary cards by parents/guardians during the 8-day post-vaccination follow-up period. For infants in the co-administration cohort, local symptoms (pain, swelling and redness) were also recorded.

The intensity of each solicited symptom was assessed on a 4-point scale (ranging from grade 0: normal to grade 3: severe), where grade 3 was defined as follows: infant cried when limb was moved/spontaneously painful (pain); \>30 mm injection site surface diameter (redness and swelling); prevented normal daily activities (cough/runny nose, irritability/fussiness, drowsiness, gastrointestinal symptoms); ≥6 looser than normal stools per day (diarrhea); ≥3 episodes of vomiting per day (vomiting), axillary temperature \>39°C (fever); did not eat at all (loss of appetite).

Unsolicited symptoms were measured during the 31-day post-RIX4414/placebo vaccination follow-up period and serious adverse events were recorded throughout the study period as previously reported.[@cit0013]

Statistical analysis {#s0005}
--------------------

All statistical analyses were performed using SAS Drug and Development web portal version 3.5.

The TVC included all infants who received at least one dose of RIX4414 or placebo. Anti-RV IgA antibody analysis was performed on the ATP cohort for immunogenicity, which included infants who: complied with vaccination and blood sampling schedules; were seronegative for serum anti-RV IgA antibodies before vaccination; had available immunogenicity data at pre- and post-sampling time points. Antibody analysis of the antigens in the co-administered vaccines was performed on subjects in the co-administration cohort, who complied with DTPa and OPV vaccination and blood sampling schedules; completed all vaccinations; had available immunogenicity data at the post-sampling time point.

Serum anti-RV IgA antibody seroconversion rates (one month post-dose 2)/seropositivity rates (at one year of age)/ GMCs (at both time points) of RIX4414 versus placebo were tabulated with 95% CI. GMCs were calculated by taking the anti-log of the mean of the log antibody concentration transformations.

For subjects in the co-administration cohort, the antibody seroprotection/seropositivity rates for anti-diphtheria, anti-tetanus, anti-PT, anti-FHA anti-PRN (one month post-dose 3 of DTPa), anti-poliovirus types 1, 2 and 3 (2 months post-dose-3 of OPV) were calculated with 95% CI.

The safety analysis was performed on the TVC. The percentage of all infants with solicited general symptoms reported during the 8-day post-vaccination follow-up period was tabulated with 95% CI. For infants in the co-administration cohort solicited local symptoms were also tabulated.
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